S. 2617

119 S2617 IS: Reducing Drug Prices for Seniors Act.
 U.S. Senate
 2025-07-31
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
  II
  119th CONGRESS
  1st Session
  S. 2617
  IN THE SENATE OF THE UNITED STATES
  July 31, 2025
  Ms. Rosen  (for herself and  Mr. Cornyn ) introduced the following bill; which was
  read twice and referred to the  Committee on
  Finance
  A BILL
To amend title XVIII of the Social Security Act to require that coinsurance
  for drugs under Medicare part D be based on the drug's net price and not the drug's list
  price.
1.
Short title
This Act may be cited as the   Reducing Drug Prices for Seniors Act.  .
2.
Requiring that coinsurance for drugs under Medicare part D be based on the
  drug's net price and not the drug's list price
Section 1860D–2 of the Social Security Act ( 42 U.S.C. 1395w–102 ) is amended—
(1)
in subsection (b)—
(A)
in paragraph (2)(A), in the matter preceding clause (i), by striking  and (9)  and inserting  , (9), and (10) ; and
(B)
by adding at the end the following new paragraph:
(10)
Requirement that coinsurance for covered part D drugs be based on the net price of the drug
(A)
In general
For plan years beginning on or after January 1, 2026, for costs above the annual deductible specified in paragraph (1) and below the annual out-of-pocket threshold specified in paragraph (4), any coinsurance amount for a covered part D drug (insofar as such covered part D drug is included on the formulary and subject to coinsurance rather than a copayment) shall be calculated based on the net price (and not the list price) of such covered part D drug if such net price is lower than the list price of such covered part D drug. The preceding sentence shall not apply to a covered part D drug described in paragraph (8) or (9).
(B)
Net price defined
In this paragraph, the term  net price  means, with respect to a covered part D drug, the negotiated price of the covered part D drug under the prescription drug plan or MA–PD plan, net of any manufacturer-provided price concessions (as defined under section 423.100 of title 42, Code of Federal Regulations (or any successor regulation)), as reported for such drug in the Detailed DIR Report (or any successor report) submitted by the sponsor or organization offering the plan for the previous plan year.
  .
(2)
in subsection (c), by adding at the end the following new paragraph:
(7)
Requirement that coinsurance for covered part D drugs be based on the net price of the drug
The coverage is provided in accordance with subsection (b)(10).
  .